All Updates

BISMARCK, N.D. –– House Bill 1283 was given a 4-1 Do Not Pass by the North Dakota Senate Business and Industry Committee on Monday following passage in the House. The bill would put North Dakotans one step closer to the peace of mind they need when it comes to breast

A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients had out-of-pocket costs for follow-up breast cancer diagnostic tests in 2023.

A new report by the American Cancer Society Cancer Action Network (ACS CAN) found that over 70% of commercially-insured patients had out-of-pocket costs for follow-up breast cancer diagnostic tests in 2023.

Washington, D.C. – As one of the leading patient advocacy groups that pushed for the passage of the Patient Protection and Affordable Care Act (ACA), the American Cancer Society Cancer Action Network (ACS CAN) is celebrating Sunday’s 15th anniversary of the historic law by highlighting its positive impacts and calling

Washington, D.C. – As one of the leading patient advocacy groups that pushed for the passage of the Patient Protection and Affordable Care Act (ACA), the American Cancer Society Cancer Action Network (ACS CAN) is celebrating Sunday’s 15th anniversary of the historic law by highlighting its positive impacts and calling

Survivors and oncology professionals share their stories with lawmakers to underscore the importance of insurance coverage of cutting-edge biomarker testing

Insurance coverage of biomarker testing will reduce health disparities for cancer patients & improve outcomes across broad spectrum of serious disease

Volunteer advocates, including cancer survivors, patients, and caregivers from across Hawaii convened at the state capitol Tuesday for ‘Cancer Action Day,’ an event hosted annually by the American Cancer Society Cancer Action Network (ACS CAN). During meetings with lawmakers, volunteers expressed desire for leaders to support policies that aim to

In a new, large national study published today in the Journal of the American Medical Association (JAMA) Network Open, American Cancer Society (ACS) researchers found the 2018 federal policy loosening restrictions on STLD insurance plans was associated with an increase in late-stage cancer diagnoses in states without or with inadequate additional STLD plan regulatory protections.